Navigation Links
Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Date:8/19/2007

n asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding these preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit,
'/>"/>

SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- SI-BONE, Inc., a medical device company that pioneered the use ... surgical (MIS) device indicated for fusion for certain disorders of ... European operations with the formation of a GmbH and the ... Germany.  Mr. Schaber will join former Kyphon colleague Andrea ... , Middle East and Asia Operations ...
(Date:10/1/2014)... R.I. , Oct. 1, 2014  CVS Health ... Month for their role in changing the way health ... improve quality in the Company,s retail pharmacies, mail service ... month, we changed our company name to CVS Health ... expertise in driving the innovations needed to shape the ...
(Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... Reportlinker.com announces that a new market ... Distributor Analysis of the ... http://www.reportlinker.com/p0552921/Distributor-Analysis-of-the-Pharmaceutical-Industry-in-Key-SADC-Countries.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... is to present an overview of the ...
... June 13, 2011 Chicago based Share Your Soles marked ... an anniversary celebration for Mona Purdy, Founder of Share Your ... shoes donated to those in need in just over a ... other special events that provide the necessary support to putting ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3Chicago Based Share Your Soles Expanding to Become Global Shoe Donation Leader 2
(Date:10/1/2014)... human eye, the brain of a rat and a ... says a QUT leading robotics researcher. , Dr ... the new study uses new computer algorithms to enable ... tunnels. , "This is a very Frankenstein type of ... of a thing together because we,re taking the eyes ...
(Date:10/1/2014)... to keep their "eyes on the prize" may be ... staying focused on a specific target ahead can make ... walk there faster, psychology researchers have found. Their study, ... the environment naturally, offers a new strategy to improve ... in exercise if physical activity seems daunting, which can ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... WASHINGTON, D.C. and ATLANTA (PRWEB) October 01, ... and information security executive networking and relationship-marketing ... the 2014 Information Security Executive® and Project ... Executives include top-ranking decision makers representing organizations ... and academics. Projects include large-scale technology endeavors ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... ... professional staff at the Atlanta gynecology clinic have introduced a Bioidentical Hormone program ... ... A. Rabin, M.D. has introduced a Bioidentical Hormones program that is highly adaptable to individual ...
... , LOS ANGELES, Sept. 18 Advocates ... Friday in response to statements he made in an LA Times story ... , , "As the Governor stepped in to stop ... office was preparing to send out similar notices to an estimated 140,000 ...
... Pharmaceuticals, a developer and manufacturer of medical products that ... 15, 2009 it received notice from the Nasdaq Stock ... Rule 5550(a)(2) because, for the previous 30 consecutive business ... closed below the minimum requirement of $1.00 per share. ...
... BOTHELL, Wash., Sept. 18 SCOLR Pharma, Inc. ... September 15, 2009, the NYSE Amex LLC (the "Exchange") accepted ... disclosed listing deficiency as set forth in Section 1003(a)(iii) of ... Company,s failure to maintain stockholder,s equity of at least $6,000,000 ...
... - revenues increase by 21% over Fiscal 2008, to $33.3 ... dollars unless otherwise noted), , , BELLEVILLE, ON, Sept. ... research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for ... had a very successful year in terms of revenues generated ...
... , , Statement of Andy Stern, ... Andy Stern, President of the Service Employees ... right wing extremists to silence working families by attacking progressive individuals ... a moment of profound change for this country -- from kitchen ...
Cached Medicine News:Health News:Dr. Rabin Introduces a Bioidentical Hormones Program Adaptable to Individual Body and Hormonal Needs 2Health News:Dr. Rabin Introduces a Bioidentical Hormones Program Adaptable to Individual Body and Hormonal Needs 3Health News:Disability Advocates Call-Out Governor Schwarzenegger for Honoring Mother-In-Law While Cutting Vital Services 2Health News:NUCRYST Receives Deficiency Notice from NASDAQ 2Health News:NUCRYST Receives Deficiency Notice from NASDAQ 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:Bioniche Reports Fiscal 2009 Year-End Results 2Health News:Bioniche Reports Fiscal 2009 Year-End Results 3Health News:Bioniche Reports Fiscal 2009 Year-End Results 4Health News:Bioniche Reports Fiscal 2009 Year-End Results 5Health News:Bioniche Reports Fiscal 2009 Year-End Results 6Health News:Bioniche Reports Fiscal 2009 Year-End Results 7Health News:Bioniche Reports Fiscal 2009 Year-End Results 8Health News:Bioniche Reports Fiscal 2009 Year-End Results 9Health News:Bioniche Reports Fiscal 2009 Year-End Results 10Health News:Bioniche Reports Fiscal 2009 Year-End Results 11Health News:Bioniche Reports Fiscal 2009 Year-End Results 12Health News:Bioniche Reports Fiscal 2009 Year-End Results 13Health News:Bioniche Reports Fiscal 2009 Year-End Results 14Health News:Bioniche Reports Fiscal 2009 Year-End Results 15Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Medicine Products: